指南与共识重症综合管理与镇静镇痛

围术期神经肌肉阻滞管理:欧洲麻醉学与重症监护学会指南

Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care.
指南 / 共识 · Eur J Anaesthesiol · 2022-11-15
一句话结论ESAIC指南推荐:使用肌松药助插管(1A),定量监测尺神经拇内收肌排除残余阻滞(1B),舒更葡糖拮抗罗库溴铵/维库溴铵深度阻滞(1A),新斯的明需TOF比>0.2后启动并监测至>0.9(1C)。

该指南由欧洲麻醉学与重症监护学会(ESAIC)制定,针对围术期神经肌肉阻滞管理提出8条推荐。基于GRADE方法学,从初始24000项研究中筛选88项临床研究,经两步Delphi流程确定专家组共识。核心推荐包括:使用肌松药助插管(1A),快速序贯诱导选用琥珀胆碱1 mg/kg或罗库溴铵0.9–1.2 mg/kg(1B),尺神经拇内收肌定量监测排除残余阻滞(1B),舒更葡糖拮抗氨基甾体类肌松药深度阻滞(1A),新斯的明需TOF比>0.2后启动并监测至>0.9(1C)。

要点

  • 推荐使用肌松药助气管插管(1A),并减少插管后咽/喉损伤(1C)
  • 快速序贯诱导推荐琥珀胆碱1 mg/kg或罗库溴铵0.9–1.2 mg/kg(1B)
  • 推荐尺神经刺激、拇内收肌定量监测排除残余阻滞(1B)
  • 舒更葡糖用于拮抗罗库溴铵/维库溴铵所致深、中、浅阻滞(1A)
  • 新斯的明拮抗需TOF比>0.2后启动,并定量监测至TOF比>0.9(1C)

适用人群与场景

  • 接受气管插管和/或腹部手术的成人患者
  • 围术期需要神经肌肉阻滞管理的成人患者

诊断标准与关键阈值

  • 残余麻痹诊断:使用尺神经刺激和拇内收肌定量神经肌肉监测排除残余麻痹(推荐1B)
  • 新斯的明拮抗启动阈值:TOF比>0.2(推荐1C)
  • 神经肌肉阻滞恢复目标:TOF比>0.9(推荐1C)

处置流程与药物剂量

  • 推荐使用肌松药助气管插管(1A)
  • 推荐使用肌松药以减少气管插管后咽和/或喉损伤(1C)
  • 快速序贯诱导插管推荐使用短效肌松药,如琥珀胆碱1 mg/kg或罗库溴铵0.9–1.2 mg/kg(1B)
  • 如需改善手术条件,推荐加深神经肌肉阻滞(1B)
  • 不推荐常规使用深度神经肌肉阻滞以减少术后疼痛或降低围术期并发症发生率(2C)
  • 推荐使用尺神经刺激和拇内收肌定量神经肌肉监测排除残余麻痹(1B)
  • 推荐使用舒更葡糖拮抗氨基甾体类肌松药(罗库溴铵、维库溴铵)引起的深、中、浅神经肌肉阻滞(1A)
  • 推荐在新斯的明拮抗前确认自主恢复(TOF比>0.2),并持续定量监测神经肌肉阻滞直至TOF比>0.9(1C)

研究设计与关键结果

  • 制定机构:欧洲麻醉学与重症监护学会(ESAIC)
  • 方法学:采用PICO问题引导结构化文献检索,初始研究24000项,最终纳入88项临床研究;使用GRADE方法学制定推荐;采用两步Delphi流程确定专家组共识
  • 推荐R1:推荐使用肌松药助气管插管(1A)
  • 推荐R2:推荐使用肌松药减少气管插管后咽和/或喉损伤(1C)
  • 推荐R3:快速序贯诱导插管推荐使用短效肌松药,如琥珀胆碱1 mg/kg或罗库溴铵0.9–1.2 mg/kg(1B)
  • 推荐R4:如需改善手术条件,推荐加深神经肌肉阻滞(1B)
  • 推荐R5:证据不足以推荐常规深度神经肌肉阻滞以减少术后疼痛或降低围术期并发症发生率(2C)
  • 推荐R6:推荐使用尺神经刺激和拇内收肌定量神经肌肉监测排除残余麻痹(1B)

证据类型、等级与局限

  • 证据类型:指南(欧洲麻醉学与重症监护学会)
  • 证据分级:GRADE方法学,推荐强度1A、1B、1C、2C
  • 局限:原文未报告局限性

对床旁实践的改变

  • 推荐使用肌松药助气管插管(1A),并减少插管后咽/喉损伤(1C)
  • 快速序贯诱导插管推荐琥珀胆碱1 mg/kg或罗库溴铵0.9–1.2 mg/kg(1B)
  • 推荐使用尺神经刺激和拇内收肌定量监测排除残余麻痹(1B)
  • 推荐舒更葡糖拮抗罗库溴铵/维库溴铵所致深、中、浅阻滞(1A)
  • 新斯的明拮抗需TOF比>0.2后启动,并定量监测至TOF比>0.9(1C)
  • 如需改善手术条件,推荐加深神经肌肉阻滞(1B)

指南或共识出处

  • 欧洲麻醉学与重症监护学会(ESAIC)围术期神经肌肉阻滞管理指南

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Recent data indicated a high incidence of inappropriate management of neuromuscular block, with a high rate of residual paralysis and relaxant-associated postoperative complications. These data are alarming in that the available neuromuscular monitoring, as well as myorelaxants and their antagonists basically allow well tolerated management of neuromuscular blockade. In this first European Society of Anaesthesiology and Intensive Care (ESAIC) guideline on peri-operative management of neuromuscular block, we aim to present aggregated and evidence-based recommendations to assist clinicians provide best medical care and ensure patient safety. We identified three main clinical questions: Are myorelaxants necessary to facilitate tracheal intubation in adults? Does the intensity of neuromuscular blockade influence a patient's outcome in abdominal surgery? What are the strategies for the diagnosis and treatment of residual paralysis? On the basis of this, PICO (patient, intervention, comparator, outcome) questions were derived that guided a structured literature search. A stepwise approach was used to reduce the number of trials of the initial research ( n = 24 000) to the finally relevant clinical studies ( n = 88). GRADE methodology (Grading of Recommendations, Assessment, Development and Evaluation) was used for formulating the recommendations based on the findings of the included studies in conjunction with their methodological quality. A two-step Delphi process was used to determine the agreement of the panel members with the recommendations: R1 We recommend using a muscle relaxant to facilitate tracheal intubation (1A). R2 We recommend the use of muscle relaxants to reduce pharyngeal and/or laryngeal injury following endotracheal intubation (1C). R3 We recommend the use of a fast-acting muscle relaxant for rapid sequence induction intubation (RSII) such as succinylcholine 1 mg kg -1 or rocuronium 0.9 to 1.2 mg kg -1 (1B). R4 We recommend deepening neuromuscular blockade if surgical conditions need to be improved (1B). R5 There is insufficient evidence to recommend deep neuromuscular blockade in general to reduce postoperative pain or decrease the incidence of peri-operative complications. (2C). R6 We recommend the use of ulnar nerve stimulation and quantitative neuromuscular monitoring at the adductor pollicis muscle to exclude residual paralysis (1B). R7 We recommend using sugammadex to antagonise deep, moderate and shallow neuromuscular blockade induced by aminosteroidal agents (rocuronium, vecuronium) (1A). R8 We recommend advanced spontaneous recovery (i.e. TOF ratio >0.2) before starting neostigmine-based reversal and to continue quantitative monitoring of neuromuscular blockade until a TOF ratio of more than 0.9 has been attained. (1C).

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

参考来源

  1. Fuchs-Buder T, Romero CS, Lewald H, et al. Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2022. PMID: 36377554. doi:10.1097/EJA.0000000000001769

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。